HeyJaredGlobal Health Insights
Opinions about global health, careers, and leadership by Peter Singer
- Indexed issues, last 90 days
- 9
- Latest publication
- Sep 28, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 14, 2026
Latest issues
Budi Gunadi Sadikin shows national results but needs a more detailed WHO plan (opens the original)
Read excerpt
In recent days, WHO Director-General candidate Budi Gunadi Sadikin launched his platform to build strong national health systems, grow regional resilience, and scale global impact. Build, Grow, Scale: the pillars spell his initials, so BGS has launched BGS. He is the second of six WHO Director-General candidates, after Hans Kluge, to publish a full platform document.I don’t know Budi. I like his platform. But he
Governments have a claim on innovation. Nobody has staked it. (opens the original)
Read excerpt
This week at the UN General Assembly, the Accra Reset panel set out how countries should take over from aid and build health sovereignty. Domestic resources become the foundation; ministries of health, finance and planning draw up the national plan together; global health agencies would be consolidated or, “where appropriate,” closed.The panel’s innovation agenda is about regional research, trials, manufacturing and pooled purchasing. It calls health an investment, but says nothing about how a f
Canada’s life sciences strategy doesn’t estimate a return. So I did. (opens the original)
Read excerpt
Many countries have life sciences strategies. A few calculate the economic benefits — GDP, jobs, investment — which accrue to businesses and households. Almost none separate those from the fiscal benefits, which accrue to governments as returns to the treasury. Conflating them hides the question a finance minister most needs answered: which of these recommendations pays us back?On 24 July 2026, Canada’s <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/
The equity paradox in GLP-1s and serious mental illness (opens the original)
Read excerpt
A man with schizophrenia, treated for years with olanzapine, was started on semaglutide for the weight the drug had put on him. It worked. Then his Medicare plan changed and coverage stopped. Over three months he regained more than twenty pounds and reached a new high. His doctors contested the denial and lost. They eventually secured free supply through a manufacturer’s assistance programme, and he has since lost twenty-five pounds — apart from three weeks when his roommate put the medicine in
Closing the science commercialization gap (opens the original)
Read excerpt
Canada has great science but struggles to turn it into economic value. Canada’s spending on higher-education R&D ranks above the G7 average, while its business R&D is among the lowest in the G7 and has been trending down for two decades. With its economic sovereignty threatened, Canada must even more urgently close the commercialization gap.The Eddie Goldenberg Research Chairs o
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.